Gilead gets Oct. 3 FDA panel

GILD said the FDA's Antiviral Advisory Committee will review on Oct. 3 the company's NDA for Viread tenofovir disoproxil fumarate to treat HIV infection/AIDS. In May, the company submitted an NDA to t...